Proposed cuts to prescriptions of vitamin D maintenance doses would hit high risk groups, the charity National Osteoporosis Society has warned.

People needing vitamin D to maintain strong bones will struggle to sustain healthy levels if plans to withdraw maintenance doses under new NHS spending cuts go ahead, it maintains.

In a response to an NHS England public consultation, the charity has raised concerns that the proposed cut to vitamins, minerals and probiotics would adversely affect people needing to maintain levels of vitamin D in order to protect their bones and guard against osteoporosis.

The charity believes that groups at high-risk of vitamin D deficiency – people with darker skin; people who are frail, housebound or living in a care home or those that usually wear clothes that cover up most of their skin when outdoors - would be particularly at risk because they cannot produce the vitamin through the usual route of exposure to sunshine.

Responding to the consultation, the charity’s Clinical Director Fizz Thompson said it was “concerning” that maintenance doses of vitamin D would no longer be prescribed in primary care if the proposed changes were pushed through.

“There is clear evidence that groups of patients at high-risk of deficiency should be maintained on vitamin D even when replete because they find it difficult to generate the vitamin through the usual route of sunlight exposure. As a result, we feel that high risk groups of patients should be maintained on prescribed vitamin D,” she said.

"Clinicians should be give the freedom to prescribe appropriately to take in to account patients individual circumstances and use NICE guidance where available and relevant . This is very much the case with people living long term with osteoporosis and at high fracture risk and vitamin D deficiency.”

Recommended

'Keep Antibiotics Working' campaign returns

This year, a bespoke version of the successful 'non-prescription pad' has been developed specifically for pharmacists.

Ground breaking therapy for children with leukaemia

Up to 30 children a year in England with ALL are to be offered the CAR-T therapy, Kymriah.




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Independent Pharmacist's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.